Sun Pharmaceutical Industries · NSE: SUNPHARMA · BSE: 524715

Q4 FY23 results · Jan–Mar 2023

Sun Pharmaceutical Industries reported revenue from operations of ₹10,930.67 crore (up 15.7% from Q4 FY22) and net profit of ₹1,982.90 crore for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY23	Q4 FY22	YoY	Q3 FY23	QoQ
Revenue from operations	10,930.67	9,446.76	+15.7%	11,240.97	−2.8%
Other income	373.28	113.59	+228.6%	173.88	+114.7%
Total income	11,303.95	9,560.35	+18.2%	11,414.85	−1.0%
Profit before share of associates & JVs and tax	2,239.69	(2,075.60)	Turned profit	2,471.47	−9.4%
Share of profit/(loss) of associates & JVs	(33.88)	(5.02)		(7.29)
Net profit for the period	1,982.90	(2,227.38)	Turned profit	2,180.75	−9.1%
Attributable to shareholders of the company	1,984.47	(2,277.25)	Turned profit	2,166.01	−8.4%
EPS, basic (₹)	8.30	(9.50)	Turned profit	9.00	−7.8%
Net margin (%)	18.1	-23.6		19.4

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY23	Q4 FY22	YoY	Q3 FY23	QoQ
Revenue from operations	5,948.22	4,006.88	+48.5%	4,645.75	+28.0%
Other income	120.30	300.41	−60.0%	68.03	+76.8%
Total income	6,068.52	4,307.29	+40.9%	4,713.78	+28.7%
Profit before tax	(1,030.27)	(800.04)	Loss widened	506.08	Turned loss
Net profit for the period	(1,020.82)	(1,286.21)	Loss narrowed	486.73	Turned loss
EPS, basic (₹)	(4.30)	(5.40)	Loss narrowed	2.00	Turned loss
Net margin (%)	-17.2	-32.1		10.5

Consolidated

Filed with BSE: 26 May 2023, 21:00 IST
Board meeting: 26 May 2023
Period: 01 Jan 2023 to 31 Mar 2023
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 26 May 2023, 21:00 IST
Board meeting: 26 May 2023
Period: 01 Jan 2023 to 31 Mar 2023
Review status: Audited
Source: XBRL filing on BSE